A Glimpse at HDL-based Therapy for Atherosclerosis.

A Glimpse at HDL-based Therapy for Atherosclerosis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A Glimpse at HDL-based Therapy for Atherosclerosis. Abstract Text:

The recent report of a high-density lipoprotein (HDL)-based treatment that reduced atherosclerotic plaques may be the first example of a new approach that is complementary to existing therapies, such as low-density lipoprotein (LDL) lowering. The treatment - infusion of a recombinant form of a naturally occurring mutant human apolipoprotein called apoA-I Milano -reduced atherosclerotic plaque volume in just 6 weeks. While follow-up replication studies involving more patients and examination of clinical end points are essential, this pilot study indicated that the atherosclerotic process can be altered by a therapy based specifically on modification of HDL.

A Glimpse at HDL-based Therapy for Atherosclerosis. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

A Glimpse at HDL-based Therapy for Atherosclerosis. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: The Clinical biochemist. Reviews / Australian Asso

VOLUME: 25

Page Numbers: 3-6

Journal Abbreviation:

ISSN: 0159-8090

DAY: 2

MONTH: Feb

YEAR: 2004

A Glimpse at HDL-based Therapy for Atherosclerosis. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8215797

A Glimpse at HDL-based Therapy for Atherosclerosis. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: A Glimpse at HDL-based Therapy for Atherosclerosis. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for A Glimpse at HDL-based Therapy for Atherosclerosis.

AFFILIATION: Blackburn Cardiovascular Genetics Laboratory, Robarts Research Institute, 406-100 Perth Drive, London, Ontario, N6A 5K8 Canada.

Country: Australia

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Biochem Rev

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A Glimpse at HDL-based Therapy for Atherosclerosis Related Publications

• A Glimpse at HDL-based Therapy for Atherosclerosis.
• Abetalipoproteinemia: two case reports and literature review.
• Adaptation to visuomotor rotations in younger and older adults.
• Association between the -455T>C promoter polymorphism of the APOC3 gene and the metabolic syndrome in a multi-ethnic sample.
• Association between the FTO rs9939609 polymorphism and the metabolic syndrome in a non-Caucasian multi-ethnic sample.
• Clinical and genetic associations with hypertriglyceridemic waist in a Canadian aboriginal population.
• Common variants APOC3, APOA5, APOE and PON1 are associated with variation in plasma lipoprotein traits in Greenlanders.
• Effect of change in posture and exercise on repolarization in patients with long QT syndrome with HERG channel mutations.
• Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome.
• Emerging antidyslipidemic drugs.
• GCK and HNF1A mutations in Canadian families with maturity onset diabetes of the young (MODY).
• Gene-environment interactions in atherosclerosis.
• Gene-environment interactions in atherosclerosis: animal models.
• Genetic determinants of plasma lipoproteins.
• Genetics of metabolic syndrome.
• Genetics of metabolic syndrome: is there a role for phenomics?
• HIV-associated dyslipidaemia: pathogenesis and treatment.
• Heterozygous CAV1 frameshift mutations (MIM 601047) in patients with atypical partial lipodystrophy and hypertriglyceridemia.
• Human hepatocyte nuclear factor-1 beta (HNF1B) 1968A/G polymorphism.
• Is raising HDL a futile strategy for atheroprotection?
• Lipoprotein (a): an emerging risk factor for atherosclerosis.
• Lipoprotein(a) and apolipoproteins B and A-I after acute myocardial infarction.
• Lipoprotein(a) and fibrinolysis.
• Lipoprotein(a): biochemistry and genetics.
• Microsomal triglyceride transfer protein inhibition-friend or foe?
• Monogenic pediatric dyslipidemias: Classification, genetics and clinical spectrum.
• Phenomics, lamin A/C, and metabolic disease.
• Single nucleotide polymorphisms of the fukutin gene.
• Spectrum of HNF1A and GCK mutations in Canadian families with maturity-onset diabetes of the young (MODY).
• The failure of torcetrapib: what have we learned?